TriangleNCT00945009 · OUTCOME
Number of Patients Without Complete Removal of at Least One Kidney
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 12 weeks from the study entry
What was measured
To evaluate the efficacy of chemotherapy in preserving renal units in children with diffuse hyperplastic perilobar nephroblastomatosis (DHPLN) and preventing Wilms tumor development.
Analysis population: Eligible and evaluable patients with diffuse hyperplastic perilobar nephroblastomatosis (DPHLN).
Groups in this outcome
Arm 3 (DHPLN)
Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
| Group | Source count |
|---|---|
| Arm 3 (DHPLN) | 9 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm 3 (DHPLN) | 7 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 7
- denoms
- counts
- group Id
- OG000
- value
- 9
- units
- Participants
- description
- To evaluate the efficacy of chemotherapy in preserving renal units in children with diffuse hyperplastic perilobar nephroblastomatosis (DHPLN) and preventing Wilms tumor development.
- groups
- description
- Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
- id
- OG000
- title
- Arm 3 (DHPLN)
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Eligible and evaluable patients with diffuse hyperplastic perilobar nephroblastomatosis (DPHLN).
- reporting Status
- POSTED
- time Frame
- 12 weeks from the study entry
- title
- Number of Patients Without Complete Removal of at Least One Kidney
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice